ALK and non-small cell lung carcinoma: The combination of atezolizumab plus bevacizumab (without additional doublet chemotherapy) was assessed in the TELMA study and was shown to be effective in the first‐line setting for patients with metastatic non‐squamous NSCLC without EGFR or ALK genomic alterations [17].